Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
NEW YORK, March 13, 2018 --
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conference:
- Oppenheimer 28th Annual Healthcare Conference on March 19, 2018 at 10:20 a.m. Eastern Time
Webcast information for this event will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
CONTACT: For more information about
Intercept Pharmaceuticals, please contact:
Intercept Pharmaceuticals:
Mark Vignola
+1-646-747-1000
[email protected]
Media inquiries: [email protected]
Investor inquiries: [email protected]
